Growing Approval Of Innovative Treatment For Soft Tissue Sarcoma is driving the Global Soft Tissue Sarcoma Market, Are Expected To Drive Market Expansion In The Near Future At A CAGR Of 7.67% During The Forecast Period 2024 To 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Soft Tissue Sarcoma Market” that contains information from 2019 to 2035.

The Global Soft Tissue Sarcoma Market is estimated to register a CAGR of 7.67% during the forecast period of 2024 to 2035.

MRFR recognizes the following companies as the key players in the Global Soft Tissue Sarcoma Market— GE HEALTHCARE, CANON MEDICAL SYSTEMS CORPORATION, NOVARTIS AG, F. HOFFMANN-LA ROCHE LTD., BLUEPRINT MEDICINES CORPORATION, JOHNSON & JOHNSON INC., BRISTOL-MYERS SQUIBB COMPANY, EISAI CO., LTD, SIEMENS HEALTHINEERS, ELI LILLY AND COMPANY.

Market Highlights

The Global Soft Tissue Sarcoma Market is estimated to register a CAGR of 7.67% during the forecast period and is estimated to reach USD 7.69 Billion by 2035.

The increasing incidence of soft tissue sarcomas is significantly driving the growth of the market for related treatments and diagnostics. As the prevalence of these rare cancers rises, fueled by factors such as genetic predispositions, environmental influences, and lifestyle changes, there is a growing demand for innovative therapeutic options and advanced diagnostic technologies. For instance, the American Cancer Society's estimated for soft tissue sarcomas in the United States for 2024 indicate a concerning trend, with approximately 13,590 new cases expected to be diagnosed, including 7,700 in males and 5,890 in females. This growing incidence underscores the urgency for improved treatment options and early detection strategies, as about 5,200 individuals (2,760 males and 2,440 females) are projected to succumb to the disease.

Moreover, according to Cancer Research UK, approximately 4,300 new cases of soft tissue sarcoma diagnosed in England each year, equating to around 12 cases per day based on data from 2017-2019. The incidence rates are notably highest among individuals aged 80-84, reflecting the increased vulnerability of older populations. Further, since the period from 2013 to 2015, there has been a 5% increase in the incidence rates of soft tissue sarcoma in England, indicating a rising trend in cases. Furthermore, according to the Canadian Cancer Society, it is estimated that in 2024, around 1,700 Canadians diagnosed with soft tissue sarcoma, which includes cases affecting the heart. Among these, approximately 960 men and 730 women were expected to be diagnosed.

Moreover, according to the World Cancer Research Fund (WCRF) International, there were 35,813 cases of Kaposi sarcoma diagnosed globally in 2022. Of these cases, approximately 24,620 were in men, while 11,193 were in women. Additionally, According to Sarcoma UK, the most common subtype of soft tissue sarcoma is gastrointestinal stromal tumors (GIST), with 927 cases diagnosed in 2019, representing nearly 1 in 5 of all sarcomas diagnosed. Following GIST, the most frequently occurring subtypes include undifferentiated sarcoma, leiomyosarcoma, and liposarcoma. the rising incidence of soft tissue sarcomas is propelling growth in the global market for treatments and diagnostics.

Access full report @ https://www.marketresearchfuture.com/reports/soft-tissue-sarcoma-market-5304

Segment Analysis

The Global Soft Tissue Sarcoma Market has been segmented based on By Product, By Technology, By End User.

Based on type, the global soft tissue sarcoma market has been segmented into Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST) and Others. The Angiosarcoma segment held the largest market in 2024 and the Gastrointestinal Stromal Tumor (GIST) segment is the fastest growing segment during the forecast period.

Based on Diagnosis and Treatment, the Global Soft Tissue Sarcoma Market has been segmented into Diagnosis and Treatment. The Diagnostic segment held the largest market in 2024 and the Treatment segment is the fastest growing segment during the forecast period. Diagnosis further segmented into Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI), and others which include PET scan, X- Ray. Treatment further segmented into Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, and Surgery.

Based on End User, the Global Soft Tissue Sarcoma Market has been segmented into Hospitals and Clinics, Cancer Research Centers and others. The Hospitals and Clinics segment held the largest market in 2024 and is the fastest growing segment during the forecast period.

Regional Analysis

Based on region, the global Soft Tissue Sarcoma market has been segmented into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America accounted for the largest market share in 2024 and is anticipated to reach USD 1,407.79 billion by 2035. However, Asia-Pacific is projected to grow at the highest CAGR of 10.05% during the forecast period. North America held the largest market share for soft tissue sarcoma in 2024 due to several key factors, including a well-established healthcare infrastructure, high awareness levels, and increased access to advanced treatment options. The region's strong presence of leading pharmaceutical companies and active research initiatives also contribute to market dominance. Rising incidence rates of soft tissue sarcoma, coupled with early diagnosis and favorable reimbursement policies, further support market growth. In addition, the U.S. government's investments in cancer research and the presence of organizations such as the National Cancer Institute (NCI) bolster innovation in therapies. By 2035, the North American soft tissue sarcoma market is projected to reach USD 1,407.79 billion, driven by continuous advancements in targeted therapies and personalized medicine. The growing aging population, along with increased clinical trials and drug approvals, will likely sustain this upward trajectory throughout the forecast period.

Asia-Pacific is projected to grow at the highest CAGR of 10.05% in the soft tissue sarcoma market during the forecast period due to several key drivers. Increasing healthcare expenditure, improving access to advanced cancer treatments, and growing awareness about rare cancers are boosting early diagnosis and treatment rates across the region. Rapid urbanization, a rising aging population, and changing lifestyles are contributing to a higher cancer burden. In addition, governments in countries like China, India, and Japan are investing heavily in healthcare infrastructure and expanding insurance coverage, making treatment more accessible. The growing presence of clinical research organizations (CROs) and increased participation in global clinical trials are fostering innovation and access to new therapies. As multinational pharmaceutical companies expand their footprint in Asia-Pacific, the region is set to become a major hub for oncology research and treatment growth.

Key Findings of the Study

• The Global Soft Tissue Sarcoma Market is expected to reach USD 7.69 Billion by 2035, at a CAGR of 7.67% during the forecast period.


• The Asia Pacific region accounted for the fastest growing in the global market.


• Based on End User, the Hospitals and Clinics segment was attributed to holding the largest market in 2024.


• GE HEALTHCARE, CANON MEDICAL SYSTEMS CORPORATION, NOVARTIS AG, F. HOFFMANN-LA ROCHE LTD., BLUEPRINT MEDICINES CORPORATION, JOHNSON & JOHNSON INC., BRISTOL-MYERS SQUIBB COMPANY, EISAI CO., LTD, SIEMENS HEALTHINEERS, ELI LILLY AND COMPANY, among others are the key market players.